
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.
Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...





